Investigating FTIR based histopathology for the diagnosis of prostate cancer

被引：88

作者：

Baker, Matthew J. ^{[1
]}

Gazi, Ehsan ^{[2
]}

Brown, Michael D. ^{[2
]}

Shanks, Jonathan H. ^{[3
]}

Clarke, Noel W. ^{[2
,4
,5
]}

Gardner, Peter ^{[1
]}

机构：

[1] Univ Manchester, Manchester Interdisciplinary Bioctr, Ctr Instrumentat & Analyt Sci, Sch Chem Engn & Analyt Sci, Manchester M1 7DN, Lancs, England

[2] Univ Manchester, Genito Urinary Canc Res Grp, Sch Canc & Imaging Sci, Paterson Inst Canc Res, Manchester M20 4BX, Lancs, England

[3] Christie Hosp NHS Trust, Dept Histopathol, Manchester M20 4BX, Lancs, England

[4] Christie Hosp NHS Trust, Dept Urol, Manchester M20 4BX, Lancs, England

[5] Salford Royal NHS Fdn Trust, Dept Urol, Salford M6 8HD, Lancs, England

来源：

JOURNAL OF BIOPHOTONICS | 2009年 / 2卷 / 1-2期

基金：

英国医学研究理事会;

关键词：

Prostate cancer (CaP); FTIR; infrared; vibrational spectroscopy; multivariate analysis; molecular diagnosis; microspectroscopy; histopathology; GLEASON GRADE; SPECTROSCOPY; BIOPSY; MICROSPECTROSCOPY; CARCINOMA; DIFFERENTIATION; PROTOCOL; BENIGN;

D O I：

10.1002/jbio.200810062

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Prostate cancer is the most common gender specific cancer. The current gold standard for diagnosis, histopathology, is subjective and limited by variation between different pathologists. The diagnostic problems associated with the correct grading and staging of prostate cancer (CaP) has led to an interest in the development of spectroscopic based diagnostic techniques. FER microspectroscopy used in combination with a Principal Component: Discriminant Function Analysis (PC-DFA) was applied to investigate FTIR based histopathology for the diagnosis of CaP In this paper we report the results of a large patient study in which FTIR has been proven to grade CaP tissue specimens to a high degree of sensitivity and specificity. (c) 2009 by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

引用

页码：104 / 113

页数：10

共 43 条

[1]

ALBERSTEN PC, 2002, JAMA-J AM MED ASSOC, V17, P2095

[2] 20-year outcomes following conservative management of clinically localized prostate cancer [J].